Amgen, Ilypsa Spin Out Relypsa To Further Cardiovascular, Renal Pipeline
This article was originally published in The Pink Sheet Daily
Executive Summary
Privately-held biopharma will have a pipeline of potassium binder drug candidates in early development.
You may also be interested in...
Relypsa Adds Venture Funds In Another Effort To Reach Phase III
Relypsa, spun out from Amgen in 2007, has raised a third round of financing in an effort to move its lead compound into late-stage development.
Amgen's Phosphate Binder Loss May Be Genzyme's Gain
Amgen is shelving its own development of the phosphate binder AMG 223 for treatment of hyperphosphatemia in chronic kidney disease, after Phase II results disappointed
Amgen's Phosphate Binder Loss May Be Genzyme's Gain
Amgen is shelving its own development of the phosphate binder AMG 223 for treatment of hyperphosphatemia in chronic kidney disease, after Phase II results disappointed